These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19079535

  • 1. The protective effect of vitamin E on locus coeruleus in early model of Parkinson's disease in rat: immunoreactivity evidence.
    Pasbakhsh P, Omidi N, Mehrannia K, Sobhani AG, Ragerdi Kashani I, Abbasi M, Kord Valeshabad A.
    Iran Biomed J; 2008 Oct; 12(4):217-22. PubMed ID: 19079535
    [Abstract] [Full Text] [Related]

  • 2. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC.
    J Comp Neurol; 2004 May 17; 473(1):97-106. PubMed ID: 15067721
    [Abstract] [Full Text] [Related]

  • 3. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J, Schmidt WJ.
    Behav Brain Res; 2004 May 05; 151(1-2):191-9. PubMed ID: 15084435
    [Abstract] [Full Text] [Related]

  • 4. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
    Bouchez G, Sensebé L, Vourc'h P, Garreau L, Bodard S, Rico A, Guilloteau D, Charbord P, Besnard JC, Chalon S.
    Neurochem Int; 2008 Jun 05; 52(7):1332-42. PubMed ID: 18372079
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
    Roghani M, Behzadi G.
    Brain Res; 2001 Feb 16; 892(1):211-7. PubMed ID: 11172767
    [Abstract] [Full Text] [Related]

  • 6. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
    Liu CQ, Chen Z, Liu FX, Hu DN, Luo JH.
    Neuropharmacology; 2007 Dec 16; 53(7):832-41. PubMed ID: 17919665
    [Abstract] [Full Text] [Related]

  • 7. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
    Chan-Palay V, Asan E.
    J Comp Neurol; 1989 Sep 15; 287(3):373-92. PubMed ID: 2570794
    [Abstract] [Full Text] [Related]

  • 8. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R, McMillan CR, Tenn CC, Niles LP.
    Brain Res; 2006 Jan 12; 1068(1):230-6. PubMed ID: 16375867
    [Abstract] [Full Text] [Related]

  • 9. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
    Wang S, Qi XJ, Han D.
    Zhongguo Zhen Jiu; 2009 May 12; 29(5):391-4. PubMed ID: 19489498
    [Abstract] [Full Text] [Related]

  • 10. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
    Andereggen L, Meyer M, Guzman R, Ducray AD, Widmer HR.
    Brain Res; 2009 Jun 18; 1276():39-49. PubMed ID: 19389387
    [Abstract] [Full Text] [Related]

  • 11. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R, McMillan CR, Niles LP.
    J Pineal Res; 2007 Oct 18; 43(3):245-54. PubMed ID: 17803521
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
    Yamamoto S, Fukae J, Mori H, Mizuno Y, Hattori N.
    Neurosci Lett; 2006 Apr 03; 396(3):187-91. PubMed ID: 16386370
    [Abstract] [Full Text] [Related]

  • 15. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
    Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW.
    Neuropharmacology; 2014 Jan 03; 76 Pt A(0 0):97-105. PubMed ID: 24025942
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Functional changes in the frontal cortex in Parkinson's disease using a rat model.
    Hou Z, Lei H, Hong S, Sun B, Fang K, Lin X, Liu M, Yew DT, Liu S.
    J Clin Neurosci; 2010 May 03; 17(5):628-33. PubMed ID: 20116257
    [Abstract] [Full Text] [Related]

  • 18. Effect of treatment with the neuroactive peptide posatirelin on microanatomical changes of frontal cortex and hippocampus caused by lesions of the locus coeruleus.
    Amenta F, Sabbatini M, Coppi G, Maggioni A, Olgiati V, Panocka I.
    Drugs Exp Clin Res; 1997 May 03; 23(2):77-88. PubMed ID: 9309383
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Locus coeruleus promotes survival of dopamine neurons in ventral mesencephalon. An in oculo grafting study.
    Berglöf E, Strömberg I.
    Exp Neurol; 2009 Mar 03; 216(1):158-65. PubMed ID: 19150447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.